Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries

Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries

IntroductionAlthough there is a significant utilization gap of biologic medicines in the EU, many studies estimate equity in patient access to biopharmaceuticals only based on their availability on the national list of reimbursed medicines. Hidden access barriers may facilitate financial sustainabil...

Full description

Bibliographic Details
Main Authors: András Inotai, Dominik Tomek, Maciej Niewada, László Lorenzovici, Martin Kolek, Jakub Weber, Anne-Katrin Kurrat, Emese Virág Kiss, Zoltán Kaló
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Pharmacology
Subjects:
rheumatoid arthritis
biologic
Central Eastern Europe
access barriers
TNF alpha inhibitor
pharmaceutical policy
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.00845/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.00845/full

Similar Items